BiotechTube
Amplo Biotechnology

Amplo Biotechnology

San Diego, United States· Est.
amplobiotechnology.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

Amplo Biotechnology is a focused, capital-efficient gene therapy company advancing a pipeline of AAV-based therapies for neuromuscular junction disorders. Its lead assets, AMP-101 (AAV-Dok7) and AMP-201 (AAV-ColQ), are in preclinical development for specific Congenital Myasthenic Syndromes, with broader potential applications in conditions like ALS and muscular dystrophy. The company employs a de-risked development approach using known technologies and has secured non-dilutive STTR funding, positioning it 10-12 months from a clinical trial application for its lead candidate.

Neuromuscular DiseasesRare DiseasesGenetic Disorders

Technology Platform

Application of established AAV vectors for muscle-targeted gene delivery to restore proteins critical for neuromuscular junction function.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

Success in initial Congenital Myasthenic Syndrome trials could validate the platform for expansion into large-market indications like ALS and muscular dystrophy, creating significant value.
The company's capital-efficient model and use of non-dilutive grant funding (STTR) enable extended runway and focused development in high-unmet-need rare diseases.

Risk Factors

High clinical risk as the novel biological approach of NMJ restoration via AAV gene therapy is unproven in humans.
The company faces intense competition in the broader neuromuscular space (e.g., ALS) from larger, well-funded entities, and the ultra-rare initial markets present commercialization challenges.

Competitive Landscape

In the niche of gene therapy for Congenital Myasthenic Syndromes, direct competition appears limited, but the space is small. For broader indications like ALS and muscular dystrophy, Amplo will compete against numerous biopharma companies developing gene therapies, antisense oligonucleotides, and other modalities. Its differentiation lies in its specific focus on NMJ biology.

More companies in Cell & Gene Therapy →More companies in United States →